Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
6
×
boston blog main
boston top stories
gene editing
san francisco blog main
biotech
boston
crispr
editas medicine
national top stories
san francisco top stories
allergan
clinical trials
crispr therapeutics
crispr-cas9
cynthia collins
deals
enzyme
feng zhang
intellia therapeutics
abbvie
agios therapeutics
alzheimer's disease
base editing
branden moriarty
broad institute
cancer
cas13
clinical study
data
david liu
david walt
diagnostics
disease
dna
drugs
editas
editor
editr
What
editing
6
×
gene
6
×
crispr
medicine
editas
cas
experimental
genetic
human
humans
medicines
therapeutics
trial
abbvie
allergan
alliance
beam
benefit
bio
biotech
blessing
bosley
cancer
cells
ceo
check
clinical
create
cusp
defect
depart
diagnostic
diseases
drive
edited
editor
exits
fears
fix
flag
Language
unset
Current search:
editing
×
gene
×
" national blog main "
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M